Professional Documents
Culture Documents
Caddfinal 170310151334
Caddfinal 170310151334
drug design
To:
Rational drug design and testing
Speed-up screening process
Efficient screening (focused, target directed)
De novo design (target directed)
Integration of testing into design process
Fail drugs fast (remove hopeless ones as early as
possible)
Types of drug design SLIDE 13
1) Ligand based drug design 2)Structure based drug design
Ligand-based drug design SLIDE 14
relies on knowledge of other
molecules that bind to the biological
target of interest.
used to derive a pharmacophore
model that defines the minimum
necessary structural characteristics a
molecule must possess in order to
bind to the target.
Ligand-based drug design
SLIDE 15
a model of the biological target may be built based on the knowledge of what
binds to it, and this model in turn may be used to design new molecular
entities that interact with the target.
Alternatively, a quantitative structure-activity relationship (QSAR), in which
a correlation between calculated properties of molecules and their
experimentally determined biological activity, may be derived. These QSAR
relationships in turn may be used to predict the activity of new analogs.
Structure-based drug design: SLIDE 16
relies on knowledge of the three
dimensional structure of the
biological target obtained through :
1. x-ray crystallography
2. NuclearMagnetic Resonance
(NMR) spectroscopy.
X-ray NMR
crystallography spectroscopy
Structure-based drug design
SLIDE 17
If an experimental structure of a target is not available,
it may be possible to create a homology model of the
target based on the experimental structure of a related
protein.
Homology modeling, also known as comparative
modeling of protein, refers to constructing an atomic-
resolution model of the "target" and an experimental
three-dimensional structure of a related homologous
protein (the "template").
Structure-based drug design
SLIDE 18
Using the structure of the biological target, candidate
drugs that are predicted to bind with high affinity and
selectivity to the target may be designed using:
interactive graphics
Intelligence of a medicinal chemist.
various automated computational procedures may be
used to suggest new drug candidates.
Methods SLIDE 19
1) Virtual screening :
The first method is identification of new ligands for a given receptor by searching large
databases of 3D structures of small molecules to find those fitting the binding pocket of
the receptor using fast approximate docking programs.
2) de novo design of new ligands:
In this method, ligand molecules are built up within the constraints of the binding pocket
by assembling small pieces in a stepwise manner. These pieces can be either individual
atoms or molecular fragments. The key advantage of such a method is that novel structures
can be suggested.
3) optimization of known ligands by evaluating proposed analogs within the binding cavity.
Binding site identification
SLIDE 20
It is the first step in structure based design.
relies on identification of concave surfaces
on the protein that can accommodate drug
sized molecules that also possess appropriate
"hot spots" (hydrophobic surfaces, hydrogen
bonding sites, etc.) that drive ligand binding.
Docking & Scoring
SLIDE 21
Docking attempts to find the “best”
matching between two molecules
It includes finding the Right Key for
the Lock
To place a ligand (small molecule) into
the binding site of a receptor in the
manners appropriate for optimal
interactions with a receptor.
To evaluate the ligand-receptor
interactions in a way that may
discriminate the experimentally
observed mode from others and
estimate the binding affinity.
Components of Docking
SLIDE 22
I- pre- and/or during docking:
Representation of receptor binding site and ligand
II- during docking:
Sampling of configuration space of the ligand-
receptor complex
III- during docking and scoring:
Evaluation of ligand-receptor interactions
Advantages of CADD
SLIDE 23
Time
Cost
Accuracy
information about the disease
screening is reduced
Database screening
less manpower is required
Success stories of CADD
SLIDE 24
K+ ion channel blocker
structural based discovery
Thrombin inhibitor
docking, de-novo design
Computational Tools
Section 02
For Drug Designing
Categories of software
SLIDE 27
1 Databases & Draw Tools
6 ADME Toxicity
Databases
SLIDE 28
ZincDatabase, Zinc15Database
ChEMBL
JChemforExcel
ProteinDataBank(PDB)
BindingMOAD(MotherOfAllDatabase)
PDBbind
STITCH,SMPDB
Databases
SLIDE 29
Databases
SLIDE 30
Draw Tools SLIDE 31
ChemDraw
MarvinSketch
ACD/ChemSketch
Marvin molecule editor and viewer
ChemWriter
UCSFChimera
Pymol
Medchem SLIDE 32
UCSF Chimera SLIDE 33
Chem Office SLIDE 34
Molecular Modeling SLIDE 35
CHARMM
GROMACS
Amber
SwissParam
CHARMM-GUI
CHARMMing.org
SwissSideChain
Hyperchem SLIDE 36
Homology Modeling SLIDE 37
Modeller
I-TASSER
LOMETS
SWISS-MODEL
SWISS-MODELRepository
Robetta
LOMETS SLIDE 38
Binding site prediction SLIDE 39
MED-SuMo
CAVER
FINDSITE
sc-PDB
Pocketome
PocketAnnotatedatabase
3DLigandSite,
metaPocket
PocketAnnotate
CAVER SLIDE 40
Docking SLIDE 41
Autodock
DOCK
GOLD
SwissDock
DockingServer
1-ClickDocking
iGemdock
iGemdock SLIDE 42
Screening SLIDE 43
Pharmer
Catalyst
PharmaGist
SwissSimilarity
Blaster
AnchorQuery
ligandscout
Discovery Studio
Discovery Studio SLIDE 44
Target prediction SLIDE 45
MolScore-Antivirals
MolScore-Antibiotics
Swiss Target Prediction
SEA
ChemProt
Ligand design SLIDE 46
GANDI
LUDI
AutoT&T2
SwissBioisostere
VAMMPIRE
sc-PDB-Frag
e-LEA3D
eDesign
iScreen
Binding free energy
estimation SLIDE 47
Hyde, X-score
NNScore
DSXONLINE
BAPPLserver
BAPPL-Zserver,
QSAR SLIDE 48
cQSAR
clogP
ClogP/CMR
MOLEdb
ChemDB/Datasets
OCHEM
E-Dragon
PatternMatchCounter
avogadro
Avogadro SLIDE 49
ADME Toxicity SLIDE 50
VolSurf
GastroPlus
MedChemStudio
ALOGPS
OSIRISPropertyExplorer
SwissADME
Metrabase
PACT-F, TOXNET
GastroPlus SLIDE 51
That’s all. Thank you very much!
Any Questions?